17th Annual Winter Lung Cancer Conference

Click here to Register

Through our partnership with PER, FLASCO members can get 50% off registration, by using the coupon code FLASCO2020*!

We are pleased to invite you to the upcoming 17th Annual Winter Lung Cancer Conference™, which will offer you a world-class continuing medical education event for the treatment of patients with lung cancer. Based on the well-received format of expert overviews with dynamic Medical Crossfire® exchanges, this meeting will provide you with the most cutting-edge research and practical information for the care of your patients, as well as offer a preview of new agents and techniques that will inform the future of lung cancer treatment.

This program, led by world-class thoracic oncologists, will offer you the chance to learn from and interact with international experts in several therapeutic areas, including immunotherapy, targeted agents, and multidisciplinary approaches. Throughout the program, question-and-answer sessions will provide the opportunity to consult with faculty and your community-based peers. Come to learn, but also to share your personal experiences and best practices in lung cancer management.

By participating in this exciting program, you will have the opportunity to learn state-of-the-art care, including:

  • How to navigate the increasing options for immunotherapy-based regimens in metastatic disease
  • How to utilize molecular testing at diagnosis and following progression on targeted therapies
  • Approaches to selecting the best therapy for oncogene-driven NSCLC
  • The use of consolidation immunotherapy in locally advanced disease
  • Current approaches with surgery and radiation oncology in patients with thoracic malignancies

Be sure to join us for the 17th Annual Winter Lung Cancer Conference™ in Miami, Florida. We look forward to seeing you there!

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Bristol-Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Pfizer; and Takeda Oncology.


Rogerio C. Lilenbaum
Rogerio C. Lilenbaum, MD
Professor of Medicine in Medical Oncology
Chief Medical Officer of Smilow Cancer Hospital – Yale New Haven Health
New Haven, CT
Mark A. Socinski
Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Member, Thoracic Oncology Program
Orlando, FL
Heather A. Wakelee
Heather A. Wakelee, MD
Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA
Julie R. Brahmer
Julie R. Brahmer, MD, MSc, FASCO
Director, Thoracic Oncology Program
Kimmel Cancer Center at Johns Hopkins Bayview
Professor of Oncology
Johns Hopkins Kimmel Cancer Center, Baltimore, MD